论文部分内容阅读
由耶鲁大学领导的一个研究小组发现了一种有前景的新联合免疫疗法,可提高机体对抗慢性病毒感染和癌症的能力。他们的研究结果发表在3月23日的《自然医学》(Nature Medicine)杂志上。尽管面对着来自机体主要抗病原体防线——T细胞的攻击,一些可引起慢性感染的病毒,如HIV和乙肝及丙肝病毒,仍能够在身体内存留。其原因在于,随着时间的推移我们的T细胞会逐渐衰弱,最终导致“T细胞耗尽”。为了战胜这
A team led by Yale University has identified a promising new combination of immunotherapy that boosts the body’s ability to fight chronic viral infections and cancers. Their findings were published in the March 23 issue of Nature Medicine. In spite of attacks from the body’s main anti-pathogen defense line, T cells, some viruses that cause chronic infections, such as HIV and hepatitis B and C viruses, can still persist in the body. The reason for this is that as time goes on, our T cells will gradually weakened, eventually resulting in “T cell depletion ”. In order to overcome this